Polysulfated glycosaminoglycan

Last updated
Polysulfated glycosaminoglycan
Polysulfated glycosaminoglycan structure.svg
Adequan packaging.jpg
Chemical structure and packaging
Clinical data
Trade names Adequan
AHFS/Drugs.com Veterinary Use
License data
Routes of
administration 		Usually IM or IA
ATCvet code
  • none
Legal status
Legal status
Pharmacokinetic data
Protein binding 30–40%
Metabolism Renal
Onset of action 48 hours for peak levels in joints (IM)
Duration of action 96 hours (IM)
Excretion Urine
Identifiers
UNII
Chemical and physical data
Molar mass 3,000–15,000 Da

Polysulfated glycosaminoglycan (PSGAG), sold under the brand name Adequan, is an injectable drug for dogs and horses that is used to alleviate the limpness, pain, and lowered range of motion caused by arthritis. [1] It is made of repeat disaccharide units (comprising hexosamine and hexuronic acid), and is similar to glycosaminoglycans already present in the cartilage; PSGAG thus easily integrates itself there. [2] [3] In vitro studies have shown it to inhibit the enzymes that degrade cartilage and bone, as well as suppress inflammation and stimulate the synthesis of replacement cartilage. While it can cause an increased risk of bleeding, it is relatively safe and has a high LD50. PSGAG is one of the most widely prescribed joint treatments for horses. [4]

Contents

While it is widely used, some studies still show conflicting results in terms of efficacy, causing some to claim that PSGAG is not solely responsible for the significant mitigation of arthritis seen in success cases. [5]

Medicinal uses

PSGAG is mostly used in dogs and horses for treating traumatic arthritis and degenerative joint disease (osteoarthritis). [6] It has shown to be better at treating acute than chronic arthritis, though some studies say that its effectiveness in acute cases is still limited if degenerative enzymes have not played a role. [7] While it is currently only FDA-approved for dogs and horses, PSGAG is also used off-label to treat lameness in swine, as a chondroprotectant ("joint protector") or treatment of interstitial cystitis in cats, and to treat arthritis in rabbits. [8] [2] [9]

Available forms

PSGAG is first administered as a series of injections over several weeks, and can be continued once or twice a month thereafter. [10] It is normally injected intramuscularly, though can also be injected intra-articularily (directly into the joint) in horses or subcutaneously in off-label uses. [1] Giving PSGAG intra-articularily requires it to be given aseptically, [7] and is sometimes supplemented by the antibiotic amikacin to prevent infection. [8] [2] [6]

There are no generic or human-labeled equivalents of PSGAG in the US. [8] [6] [10]

Side effects and overdose

Side effects from intra-articular administration can include joint pain, swelling, lameness, and, rarely, infection of the joint. Intramuscular injection can cause dose-dependent inflammation and bleeding, since PSGAG is an analogue of the anticoagulant heparin. [3] In dogs, this may manifest as bleeding from the nose or as bloody stools. [6] The increased risk of bleeding has some advising not to give PSGAG to animals with bleeding disorders, though its only absolute contraindication is hypersensitivity to PSAGs when it is being given intra-articularily. [8] [10]

Overdose on PSGAG is quite rare, as the LD50 is over 1000 mg/kg when given intravenously to dogs. Signs of overdose include exacerbated side effects such as joint pain, swelling, and lameness. [3] [6] When dogs received three times the normal dose intramuscularly twice a week for 13 weeks, they had increased liver and kidney weight, as well as microscopic lesions on the liver, kidneys, and lymph nodes. At 11 times the normal dose, they also had increased alanine transferase, cholesterol, and prothrombin time (i.e. coagulation via the extrinsic pathway took longer), and fewer platelets. [11]

Pharmacology

Mechanism of action

The cartilage matrix. The joint space is filled with synovial fluid. Glycosaminoglycans are attached to proteins, which are attached to a strand of hyaluronic acid to create a "bottle brush". Glycosaminoglycans.png
The cartilage matrix. The joint space is filled with synovial fluid. Glycosaminoglycans are attached to proteins, which are attached to a strand of hyaluronic acid to create a "bottle brush".

Normally, joint cartilages have proteoglycan complexes, which are proteins with side chains made of glycosaminoglycans such as keratan sulfate and chondroitin sulfate attached to strands of hyaluronic acid. The glycosaminoglycan side chains are polyanionic, which causes adjacent side chains to push each other away and create a "bottle brush", where hyaluronic acid is the stem and the side chains are the bristles. When pressure is exerted on the joint, fluids move between the chondrocytes and synovial fluid, exchanging nutrients. [3]

In degenerative joint disease, the proteoglycan complexes start disappearing, and the hyaluronate becomes poorer in quality and scarcer. This lowers the viscosity of the synovial fluid (which increases friction) and causes white blood cells and enzymes to enter and effect cartilage degradation and inflammation. Steroids that are released as a result kill the chondrocytes. The remaining chondrocytes have trouble exchanging nutrients with the synovial fluid, which would allow them to repair some damages. [3]

The mechanism of PSGAG in vivo is based on observations and studies in vitro. PSGAG inhibits many of the catabolic enzymes that degrade cartilage, proteoglycans, and hyaluronic acid. [5] [10] The enzymes that are inhibited include serine proteases, which play a role in the IL-1 degradation of proteoglycans and collagen; lysosomal enzymes that cause proteoglycans to dissociate from hyaluronic acid; elastase; metalloproteinases such as stromelysin, which degrade cartilage matrix proteins; collagenases such as cathepsin B1; and hyaluronidase. [3] [12] PSGAG inhibits the synthesis of prostaglandin E2, which is released upon joint injury and causes inflammation, increases the loss of proteoglycan, and reduces the threshold of pain receptors. [2] [11] [12] Inhibiting the complement pathway further reduces inflammation, most likely by altering C-reactive protein. The inhibition of blood coagulation reduces resultant fibrinolysis, which would cause cell death and increase local inflammation. [1] [3]

PSGAG also stimulates the synthesis of glycosaminoglycans, hyaluronic acid, and collagen, which increase synovial viscosity. [2] It cannot, however, completely reverse the disappearance of cartilage, nor can it reverse bone loss caused by arthritis. [12] [10]

Pharmacokinetics

PSGAG reaches peak blood concentration in 20–40 minutes when injected intramuscularly; 30–40% of it binds to blood proteins. It enters all tissues, reaching cartilage within two hours. [12] When PSGAG reaches the synovial fluid, it is then taken up by the cartilage matrices, with osteoarthritic cartilage showing a stronger preference for taking it up. [2] [11] It reaches its peak levels in the joints at 48 hours, and lasts up to 96 hours, before leaving and being excreted by the kidneys. [8] [3]

See also

Related Research Articles

<span class="mw-page-title-main">Cartilage</span> Resilient and smooth elastic tissue present in animals

Cartilage is a resilient and smooth type of connective tissue. It is a semi-transparent and non-porous type of tissue. It is usually covered by a tough and fibrous membrane called perichondrium. In tetrapods, it covers and protects the ends of long bones at the joints as articular cartilage, and is a structural component of many body parts including the rib cage, the neck and the bronchial tubes, and the intervertebral discs. In other taxa, such as chondrichthyans and cyclostomes, it constitutes a much greater proportion of the skeleton. It is not as hard and rigid as bone, but it is much stiffer and much less flexible than muscle. The matrix of cartilage is made up of glycosaminoglycans, proteoglycans, collagen fibers and, sometimes, elastin. It usually grows quicker than bone.

<span class="mw-page-title-main">Canine hip dysplasia</span> Joint abnormality in dogs

In dogs, hip dysplasia is an abnormal formation of the hip socket that, in its more severe form, can eventually cause lameness and arthritis of the joints. It is a genetic (polygenic) trait that is affected by environmental factors. It is common in many dog breeds, particularly the larger breeds, and is the most common single cause of arthritis of the hips.

Glucosamine (C6H13NO5) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Glucosamine is part of the structure of two polysaccharides, chitosan and chitin. Glucosamine is one of the most abundant monosaccharides. Produced commercially by the hydrolysis of shellfish exoskeletons or, less commonly, by fermentation of a grain such as corn or wheat, glucosamine has many names depending on country.

<span class="mw-page-title-main">Synovial fluid</span> Fluid found in the cavities of synovial joints

Synovial fluid, also called synovia,[help 1] is a viscous, non-Newtonian fluid found in the cavities of synovial joints. With its egg white–like consistency, the principal role of synovial fluid is to reduce friction between the articular cartilage of synovial joints during movement. Synovial fluid is a small component of the transcellular fluid component of extracellular fluid.

<span class="mw-page-title-main">Hyaluronic acid</span> Anionic, nonsulfated glycosaminoglycan

Hyaluronic acid, also called hyaluronan, is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues. It is unique among glycosaminoglycans as it is non-sulfated, forms in the plasma membrane instead of the Golgi apparatus, and can be very large: human synovial HA averages about 7 MDa per molecule, or about 20,000 disaccharide monomers, while other sources mention 3–4 MDa.

<span class="mw-page-title-main">Monoarthritis</span> Medical condition

Monoarthritis, or monoarticular arthritis, is inflammation (arthritis) of one joint at a time. It is usually caused by trauma, infection, or crystalline arthritis.

<span class="mw-page-title-main">Pentosan polysulfate</span> Chemical compound

Pentosan polysulfate, sold under the brand name Elmiron among others, is a medication used for the treatment of interstitial cystitis. It was approved for medical use in the United States in 1996.

<span class="mw-page-title-main">Chondroblast</span> Mesenchymal progenitor cell that forms a chondrocyte

Chondroblasts, or perichondrial cells, is the name given to mesenchymal progenitor cells in situ which, from endochondral ossification, will form chondrocytes in the growing cartilage matrix. Another name for them is subchondral cortico-spongious progenitors. They have euchromatic nuclei and stain by basic dyes.

Osselet is arthritis in the fetlock joint of a horse, caused by trauma. Osselets usually occur in the front legs of the horse, because there is more strain and concussion on the fetlock there than in the hind legs. The arthritis will occur at the joint between the cannon bone and large pastern bone, at the front of the fetlock.

Synovectomy is the surgical removal of the synovial tissue surrounding a joint. This procedure is typically recommended to provide relief from a condition in which the synovial membrane or the joint lining becomes inflamed and irritated and is not controlled by medication alone. If arthritis is not controlled, it can lead to irreversible joint damage. The synovial membrane or "synovium" encloses each joint and also secretes a lubricating fluid that allows different joint motions such as rolling, folding and stretching. When the synovium becomes inflamed or irritated, it increases fluid production, resulting in warmth, tenderness, and swelling in and around the joint.

<span class="mw-page-title-main">Aggrecan</span>

Aggrecan (ACAN), also known as cartilage-specific proteoglycan core protein (CSPCP) or chondroitin sulfate proteoglycan 1, is a protein that in humans is encoded by the ACAN gene. This gene is a member of the lectican (chondroitin sulfate proteoglycan) family. The encoded protein is an integral part of the extracellular matrix in cartilagenous tissue and it withstands compression in cartilage.

<span class="mw-page-title-main">Proteoglycan 4</span> Proteoglycan; lubricant; gene

Proteoglycan 4 or lubricin is a proteoglycan that in humans is encoded by the PRG4 gene. It acts as a joint/boundary lubricant.

Crystal arthropathy is a class of joint disorder that is characterized by accumulation of tiny crystals in one or more joints. Polarizing microscopy and application of other crystallographic techniques have improved identification of different microcrystals including monosodium urate, calcium pyrophosphate dihydrate, calcium hydroxyapatite, and calcium oxalate.

<span class="mw-page-title-main">Sodium hyaluronate</span> Chemical compound

Sodium hyaluronate is the sodium salt of hyaluronic acid, a glycosaminoglycan found in various connective tissue of humans.

Fibroblast-like synoviocytes (FLS) represent a specialised cell type located inside joints in the synovium. These cells play a crucial role in the pathogenesis of chronic inflammatory diseases, such as rheumatoid arthritis.

The treatment of equine lameness is a complex subject. Lameness in horses has a variety of causes, and treatment must be tailored to the type and degree of injury, as well as the financial capabilities of the owner. Treatment may be applied locally, systemically, or intralesionally, and the strategy for treatment may change as healing progresses. The end goal is to reduce the pain and inflammation associated with injury, to encourage the injured tissue to heal with normal structure and function, and to ultimately return the horse to the highest level of performance possible following recovery.

A chondroprotective compound is a specific compound or chemical that delays progressive joint space narrowing characteristic of arthritis and improves the biomechanics of articular joints by protecting chondrocytes. These agents perform various functions, such as:

  1. Stimulating chondrocyte synthesis of collagen and proteoglycans
  2. Enhancing synoviocyte production of hyaluronan
  3. Inhibiting cartilage degradation
  4. Preventing fibrin formation in the vasculature

Artificial cartilage is a synthetic material made of hydrogels or polymers that aims to mimic the functional properties of natural cartilage in the human body. Tissue engineering principles are used in order to create a non-degradable and biocompatible material that can replace cartilage. While creating a useful synthetic cartilage material, certain challenges need to be overcome. First, cartilage is an avascular structure in the body and therefore does not repair itself. This creates issues in regeneration of the tissue. Synthetic cartilage also needs to be stably attached to its underlying surface i.e. the bone. Lastly, in the case of creating synthetic cartilage to be used in joint spaces, high mechanical strength under compression needs to be an intrinsic property of the material.

A disease-modifying osteoarthritis drug (DMOAD) is a disease-modifying drug that would inhibit or even reverse the progression of osteoarthritis. Since the main hallmark of osteoarthritis is cartilage loss, a typical DMOAD would prevent the loss of cartilage and potentially regenerate it. Other DMOADs may attempt to help repair adjacent tissues by reducing inflammation. A successful DMOAD would be expected to show an improvement in patient pain and function with an improvement of the health of the joint tissues.

Radiosynoviorthesis (RSO) is a minimally invasive therapeutic procedure for managing joint inflammation, particularly synovitis associated with osteoarthritis. Radiosynoviorthesis involves the intra-articular injection of radioactive isotopes to specifically treat the inflamed synovial membrane. Synovitis, a hallmark of various joint disorders, including osteoarthritis, manifests as inflammation within the synovial membrane lining the joints. RSO aims to suppress overactive macrophage and synovial cells responsible for the inflammatory response, providing relief from pain and improving joint functionality.

References

  1. 1 2 3 Goldberg ME (2014-10-23). Pain Management for Veterinary Technicians and Nurses. John Wiley & Sons. p. 140. ISBN   9781118811160.
  2. 1 2 3 4 5 6 Wanamaker BP, Massey K (2014-03-25). Applied Pharmacology for Veterinary Technicians – E-Book. Elsevier Health Sciences. p. 392. ISBN   9780323291705.
  3. 1 2 3 4 5 6 7 8 White GW (1988-11-01). "Adequan: A review for the practicing veterinarian". Journal of Equine Veterinary Science. 8 (6): 463–468. doi:10.1016/S0737-0806(88)80096-0. ISSN   0737-0806. Closed Access logo transparent.svg
  4. ↑ Bryant JO (2012-12-10). The USDF Guide to Dressage: The Official Guide of the United States Dressage Foundation. Storey Publishing. p. 285. ISBN   9781612122748.
  5. 1 2 Schulz K, Beale B, Holsworth I (2005). The Pet Lover's Guide to Canine Arthritis & Joint Problems. Elsevier Health Sciences. p. 192. ISBN   9781416026143.
  6. 1 2 3 4 5 "Patient Information Sheet" (PDF). Doctor Foster and Smith Pharmacy. 2007-09-14. Retrieved 2017-07-10.
  7. 1 2 Papich MG (2007). "Polysulfated Glycosaminoglycan". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 537–538. ISBN   9781416028888.
  8. 1 2 3 4 5 Plumb DC (2011). "Polysulfated glycosaminoglycan (PSGAG)". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 837–839. ISBN   9780470959640.
  9. ↑ Khuly P (2010-03-05). "Why I Love Adequan for Cats and Dogs". PetMD. Retrieved 2017-07-10.
  10. 1 2 3 4 5 "Adequan Canine Injectable (Prescription)". Doctors Foster and Smith. Retrieved 2017-07-10.
  11. 1 2 3 US National Library of Medicine (2016-08-24). "Adequan Canine". DailyMed. Retrieved 2017-07-10.
  12. 1 2 3 4 Fox SM (2009-12-15). Chronic Pain in Small Animal Medicine. CRC Press. pp. 197–200. ISBN   9781840765670.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.